AGPU Axe Compute Inc.
USTechnologyAs of 2026-08-06
Why AGPU matters now
Axe Compute Inc. (AGPU) is a US stock in Technology. The latest InvestLog snapshot shows $8.38 with -8.81% on the session and $96.3M in market capitalization; recent performance reads 1-month +49.58% and YTD -0.42%.
The latest financial table shown here is Q1 2026, with revenue of $35.3K, net income of $-7.7M, and EPS of $-0.36. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -51.7%.
The latest indexable market news headline is "Axe Compute to Host Q2 2026 Financial Results Conference Call" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Zhu Theodore filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.75
P/S
480.50
EV/EBITDA
-0.08
DCF Value
$0.77
FCF Yield
-51.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-325.2%
Operating Margin
-58805.9%
Net Margin
-474020.6%
ROE
-10705.2%
ROA
-527.1%
ROIC
-70.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $35.3K | $-7.7M | $-0.36 |
| Q4 2025 | $8.7K | $-150.9M | $-36.97 |
| FY 2025 | $125.3K | $-233.1M | $-13.37 |
| Q3 2025 | $3.6K | $-77.7M | $-107.25 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Technology
Industry
Software - Infrastructure
Country
US
Exchange
—
Beta
3.48
Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.